1. Search Result
Search Result
Results for "

Lymphomas

" in MedChemExpress (MCE) Product Catalog:

734

Inhibitors & Agonists

3

Screening Libraries

5

Fluorescent Dye

6

Biochemical Assay Reagents

22

Peptides

115

Inhibitory Antibodies

47

Natural
Products

28

Isotope-Labeled Compounds

3

Click Chemistry

14

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-109108
    Valemetostat
    5 Publications Verification

    DS-3201

    Histone Methyltransferase Cancer
    Valemetostat (DS-3201), a first-in-class EZH1/2 dual inhibitor with IC50 values <10 nM. Valemetostat can be used for the research of relapsed/refractory peripheral T-cell lymphoma .
    Valemetostat
  • HY-P99055

    TNF Receptor Inflammation/Immunology Cancer
    Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
    Urelumab
  • HY-169179

    PROTACs STAT Cancer
    AK-1690 is a selective PROTAC degrader targeting STAT6 (DC50=1 nM) with a Ki of 6 nM against human STAT6. AK-1690 degrades STAT6 via the interaction of STAT6 with cereblon and a ubiquitin-like process. AK-1690 effectively depletes STAT6 protein in mouse liver and lung tissues, and is applicable to research related to leukemia, Hodgkin's lymphoma, follicular lymphoma, etc. .
    AK-1690
  • HY-148026

    BGB 11417

    Bcl-2 Family Cancer
    Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines .
    Sonrotoclax
  • HY-158105
    ARV-393
    1 Publications Verification

    PROTACs BCL6 Cancer
    ARV-393 is a potent and orally active BCL6 PROTAC degrader. ARV-393 induces ubiquitination of BCL6 and its subsequent degradation by the proteasome. ARV-393 has the potential for the research of advanced non-hodgkin lymphoma .
    ARV-393
  • HY-160141

    BGB-16673; BTK-IN-29

    PROTACs Btk NF-κB Inflammation/Immunology Cancer
    BGB-16673 (BGB-16673) is an orally active, selective BTK PROTAC degrader (IC50=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .
    Catadegbrutinib
  • HY-P99056

    PF 05082566

    TNF Receptor Inflammation/Immunology Cancer
    Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20 + non-Hodgkin lymphomas .
    Utomilumab
  • HY-P99289

    Antibody hLL 2; AMG-412

    CD22 Inflammation/Immunology Cancer
    Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
    Epratuzumab
  • HY-172320

    PD-1/PD-L1 Cancer
    BMS-986238 is an orally active macrocyclic peptide PD-L1 inhibitor. BMS-986238 can be used in the research of tumors such as solid tumors and lymphomas .
    BMS-986238
  • HY-P99483

    AT 004; VT 007

    CD20 Cancer
    Blontuvetmab (AT 004) is a canine-derived CD20 monoclonal antibody, and it is used for research on canine B-cell lymphoma .
    Blontuvetmab
  • HY-120231

    MALT1 NF-κB MMP Cancer
    Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .
    Z-VRPR-FMK
  • HY-157783

    DNA/RNA Synthesis Cancer
    Dencatistat is a CTP synthetase 1 (b) inhibitor. CTPS1 is a key rate-limiting enzyme that catalyzes the conversion of UTP to CTP. Dencatistat can be used for research on lymphoma .
    Dencatistat
  • HY-147091

    Ligands for Target Protein for PROTAC Cancer
    Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein EZH2, which can be used to synthesis of EZH2 degraders (PROTACs). EZH2 degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .
    Tazemetostat de(methyl morpholine)-COOH
  • HY-P99613

    MK-4280; Mavezelimab

    LAG-3 Cancer
    Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma . For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Favezelimab
  • HY-147090

    Histone Methyltransferase Target Protein Ligand-Linker Conjugates Cancer
    Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) incorporates a ligand for EZH2, and a PROTAC linker, which recruit E3 ligases. Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH (Compound 21b) can be used for the research of lymphoma .
    Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH
  • HY-P99273

    TNF Receptor Cancer
    Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma .
    Vorsetuzumab
  • HY-P99674

    GEN-3009

    Transmembrane Glycoprotein Cancer
    Ivicentamab (GEN-3009) is a bispecific antibody targeting CD37 with dual epitopes. Ivicentamab carries an E430G mutation in the Fc region, which efficiently promotes IgG hexamer formation on the surface of target cells. Ivicentamab provides the parental variable regions for an H429F-engineered anti-CD37 bispecific antibody, enabling it to exert complement-dependent cytotoxicity in Daudi lymphoma cells. Ivicentamab is mainly used in lymphoma-related research .
    Ivicentamab
  • HY-P99326

    Anti-Human CD20 Recombinant Antibody; V10XA53

    CD20 Cancer
    Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
    Tositumomab
  • HY-P99253
    Mogamulizumab
    1 Publications Verification

    KW-0761

    CCR Inflammation/Immunology Cancer
    Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
    Mogamulizumab
  • HY-129226

    SHMT Endocrinology Cancer
    SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC50 values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas .
    SHMT-IN-2
  • HY-144288

    Btk Cancer
    BLK-IN-2 (compound 25) is a potent and selective irreversible inhibitor of B-Lymphoid tyrosine kinase (BLK), with an IC50 of 5.9 nM. BLK-IN-2 also inhibits BTK (IC50=202.0 nM). BLK-IN-2 shows potent antiproliferative activities against several lymphoma cells .
    BLK-IN-2
  • HY-131246

    Histone Methyltransferase Cancer
    DM-01 is a powerful and selective EZH2 inhibitor for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and SNF5/INI-1/SMARCB1 genetically defined solid tumors .
    DM-01
  • HY-174371

    Molecular Glues Casein Kinase MDM-2/p53 MALT1 Neurological Disease Cancer
    INNO-220 is an orally active, CRBN-dependent molecular glue degrader targeting CK1α. INNO-220 induces cell cycle arrest at G0/G1 phase and triggers apoptosis by degrading CK1α. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, thereby inhibiting NF-κB signaling in stimulated T cells and lymphoma cells that harbor an activating mutation in CARD11. INNO-220 provides a new direction for lymphoma research.
    INNO-220
  • HY-19990

    Anaplastic lymphoma kinase (ALK) Cancer
    ALK kinase inhibitor-1 is an anaplastic lymphoma kinase (ALK) inhibitor extracted from patent US20130261106A1 compound I-202 .
    ALK kinase inhibitor-1
  • HY-169245

    CDK BCL6 Cancer
    DK-TCIP2, linking inhibitor of CDK9 SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer .
    CDK-TCIP2
  • HY-161765

    HSP STAT Cancer
    iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
    iHSP110-33
  • HY-132601A

    MRG-106 sodium

    MicroRNA Cancer
    Cobomarsen sodium is an oligonucleotide inhibitor of miR-155. Cobomarsen sodium inhibits multiple gene pathways associated with cell survival (including JAK/STAT, MAPK/ERK and PI3K/AKT). Cobomarsen sodium can be used for the research of B-cell lymphoma .
    Cobomarsen sodium
  • HY-160520

    Anaplastic lymphoma kinase (ALK) Cancer
    ALK-IN-28 (compound 22) is an inhibitor of anaplastic lymphoma kinase (ALK) .
    ALK-IN-28
  • HY-W017194

    Biochemical Assay Reagents HIV Infection Cancer
    2-Phenylbutanoic acid is a monocarboxylic acid. 2-Phenylbutanoic acid interacts with proteins. 2-Phenylbutanoic acid is used in the study of malignant lymphoma and HIV virus-related diseases .
    2-Phenylbutanoic acid
  • HY-P99501

    HS006

    CD20 Cancer
    Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .
    Zuberitamab
  • HY-P1258
    PSI
    2 Publications Verification

    Proteasome Inhibitor 1; Z-Ile-Glu(OtBu)-Ala-Leu-CHO

    Proteasome Infection Cancer
    PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .
    PSI
  • HY-P99952

    SCT400

    CD20 Cancer
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
    Ripertamab
  • HY-14171S

    LGD1069 d4

    RAR/RXR Autophagy Cancer
    Bexarotene-d4 is a deuterium labeled Bexarotene (LGD1069). Bexarotene (LGD1069) is a selective retinoid X receptors (RXR) agonist for the treatment of cutaneous T-cell lymphoma .
    Bexarotene-d4
  • HY-123950

    MDM-2/p53 Apoptosis Cancer
    MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .
    MMRi64
  • HY-106582

    MST 16

    Topoisomerase Neurological Disease Cancer
    Sobuzoxane (MST-16) is an orally active topoisomerase II inhibitor. Sobuzoxane causes irreversible inhibition of cell division. Sobuzoxane can be used in the study of non-Hodgkin's lymphoma that is resistant to conventional chemotherapy or has recurred .
    Sobuzoxane
  • HY-148281

    Bcl-2 Family Cancer
    TMX-2164 is a potent, irreversible B-cell lymphoma 6 (BCL6) inhibitor with an IC50 value of 152 nM. TMX-2164 displays sustained target engagement and antiproliferative activity in cells .
    TMX-2164
  • HY-153320

    MAP3K Cancer
    AZ-TAK1, an ATP-competitive small molecule inhibitor of TAK1, dephosphorylates TAK1, p38, and IκB-α in lymphoma cell lines .
    AZ-TAK1
  • HY-134039
    5-Hydroxy-8-methoxypsoralen
    1 Publications Verification

    5-Hydroxyxanthotoxin

    Drug Metabolite Inflammation/Immunology
    5-Hydroxy-8-methoxypsoralen (5-Hydroxyxanthotoxin) is a metabolite of Xanthotoxin. Xanthotoxin is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight .
    5-Hydroxy-8-methoxypsoralen
  • HY-P991345

    AMP-514

    PD-1/PD-L1 Cancer
    MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
    MEDI-0680
  • HY-109029

    INCB040093

    PI3K Cancer
    Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .
    Dezapelisib
  • HY-159817

    Bcl-2 Family Cancer
    Asaretoclax is a potent B-cell lymphoma 2 (Bcl-2) inhibitor. Asaretoclax has the potential for the research of cancer .
    Asaretoclax
  • HY-P99619

    SCT-I10A

    PD-1/PD-L1 Cancer
    Finotonlimab (SCT-I10A) is a recombinant humanised IgG PD-1 antibody. Finotonlimab has the potential for solid tumors or lymphomas research .
    Finotonlimab
  • HY-185206

    PROTACs Itk NF-κB Cancer
    BSJ-05-037 is an ITK PROTAC degrader that effectively targets and degrades ITK in T-cell lymphoma cell lines. BSJ-05-037 blocks the activation of the NF-κB/GATA-3 signaling pathway, inhibits PLCγ1 phosphorylation, and reduces the proliferative capacity of T-cell lymphoma cells. BSJ-05-037 enhances the sensitivity of T-cell lymphoma cells to chemotherapy. In mouse models of T-cell lymphoma, BSJ-05-037 induces ITK degradation, reduces GATA-3 expression, decreases tumor volume, and reverses chemotherapy resistance. BSJ-05-037 is applicable to research related to T-cell lymphoma .
    BSJ-05-037
  • HY-N12122

    Fungal Neurological Disease
    Dehydropipernonaline (Compound 24) is an amide compound. Dehydropipernonaline shows considerable cytotoxicity to L5178Y mouse lymphoma cells (IC508.9μM). Dehydropipernonaline can be used for screening antifungal and cytotoxicity .
    Dehydropipernonaline
  • HY-150594

    IRAK NF-κB Cancer
    IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM . IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research .
    IRAK4-IN-17
  • HY-N1168

    Aurora Kinase Cancer
    Tenacigenin B is a steroid that can be isolated from the genus Alocasia. Tenacigenin B has anti-tumor effects on lymphoma via regulation of Aurora-A .
    Tenacigenin B
  • HY-176172

    Btk Cancer
    BTK-IN-44 (Compound 10) is a potent noncovalent inhibitor of Bruton’s tyrosine kinase (BTK) with an IC50 value of 24.7 nM. BTK-IN-44 interferes with signaling pathways of B cell malignancies, showing antitumor effects in lymphoma cells. BTK-IN-44 is promising for research of B cell malignancies (such as lymphoma) .
    BTK-IN-44
  • HY-150019

    PI3K Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    PI3K-IN-36 (compound A68) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL) .
    PI3K-IN-36
  • HY-122115

    Histone Methyltransferase Cancer
    DCE_42 is a potent EZH2 inhibitor with an IC50 value of 22.6 µM. DCE_42 inhibits cell proliferation and has the potential for the research of lymphoma .
    DCE_42
  • HY-P1258A

    Proteasome Inhibitor 1 TFA; Z-Ile-Glu(OtBu)-Ala-Leu-CHO TFA

    Proteasome Infection Cancer
    PSI (TFA) is a potent proteasome inhibitor. PSI (TFA) inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI (TFA) can be used for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas .
    PSI TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: